EGFR and non-small cell lung carcinoma: The dramatic improvement in the prognosis of patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) became possible thanks to the advent of EGFR-tyrosine kinase inhibitors (EGFR-TKIs).